BIOTECHNOLOGY

VERAXA Biotech’s majority shareholders are Xlife Sciences AG (SIX: XLS), a Swiss-based publicly listed life science incubator fund, the European Molecular Biology Laboratory (“EMBL”), and its technology transfer arm EMBLEM.

The Institutional Review Board Has Approved the Increase in Number of Patients from Sixty (60) to Ninety (90). The Company to Expand the Study into Additional Trial Sites in Europe.

As this biomarker can be detected in blood, this test is a minimally invasive and broadly accessible diagnostic tool that may facilitate earlier detection of AD.

The presentation is scheduled for April 23, 2025, at 12:25 PM ET, Room 206 at the Walter E. Washington Convention Center, Washington, D.C.

During the presentation, Mr. Emalfarb will provide an overview of recent preclinical research utilizing Dyadic’s proprietary C1 expression platform, including data related to the production of non-mRNA antigens and reagents for vaccine production.

The Octave MSDA Test is being used by leading MS Centers of Excellence, academic institutions, and independent neurology practices across the United States, providing clinicians with critical biomarker-driven insights to support treatment decisions.